This study reveals higher fasting ANGPTL3 levels that developed MACEs in patients with CAD during follow-up, and serum ANGPTL3 levels are independently associated with an increased risk of MACEs in these patients. This evidence concerns the gene ANGPTL3 and coronary artery disorder.